These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27021324)

  • 61. Relevance of timing for determination of posaconazole plasma concentrations.
    Heinz WJ; Zirkel J; Kuhn A; Schirmer D; Lenker U; Keller D; Klinker H
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3621-3. PubMed ID: 21502619
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
    Sime FB; Stuart J; Butler J; Starr T; Wallis SC; Pandey S; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581122
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.
    McKeage K
    Drugs; 2015 Mar; 75(4):397-406. PubMed ID: 25595699
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
    Welch S; Pallotta A; Weber C; Siebenaller C; Cober E; Neuner E
    Mycoses; 2017 Apr; 60(4):241-243. PubMed ID: 27910211
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis.
    Sugimoto M; Yonezawa A; Kanda J; Itohara K; Hira D; Yamagiwa T; Taniguchi R; Hanyu Y; Watanabe M; Arai Y; Mizumoto C; Kitawaki T; Kondo T; Yamashita K; Takaori-Kondo A; Terada T
    Ther Drug Monit; 2024 Oct; 46(5):611-618. PubMed ID: 38648638
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis.
    Stuckey L; Clark Ojo T; Park JM; Annesley T; Bartos C; Cibrik DM
    Ther Drug Monit; 2014 Apr; 36(2):148-51. PubMed ID: 24232127
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
    Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
    Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
    Hummert SE; Green MR
    Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
    Boonsathorn S; Cheng I; Kloprogge F; Alonso C; Lee C; Doncheva B; Booth J; Chiesa R; Irwin A; Standing JF
    Clin Pharmacokinet; 2019 Jan; 58(1):53-61. PubMed ID: 29679234
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
    Knoop C; Vervier I; Thiry P; De Backer M; Kovarik JM; Rousseau A; Marquet P; Estenne M
    Transplantation; 2003 Aug; 76(4):683-8. PubMed ID: 12973109
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.
    Kane Z; Cheng I; McGarrity O; Chiesa R; Klein N; Cortina-Borja M; Standing JF; Gastine S
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0007723. PubMed ID: 37260401
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration.
    Gharibi S; Kimble B; Vogelnest L; Barnes J; Stadler CK; Govendir M
    J Vet Pharmacol Ther; 2017 Dec; 40(6):675-681. PubMed ID: 28455999
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
    Miceli MH; Perissinotti AJ; Kauffman CA; Couriel DR
    Mycoses; 2015 Jul; 58(7):432-6. PubMed ID: 26102575
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
    Cornely OA; Helfgott D; Langston A; Heinz W; Vehreschild JJ; Vehreschild MJ; Krishna G; Ma L; Huyck S; McCarthy MC
    Antimicrob Agents Chemother; 2012 May; 56(5):2652-8. PubMed ID: 22290953
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
    Lin TY; Yang MH; Chang FY
    Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
    Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
    BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.
    Chae H; Cho SY; Yu H; Cha K; Lee S; Kim M; Kim Y; Kim YJ; Kim HJ; Lee DG
    Clin Chim Acta; 2015 Oct; 450():220-6. PubMed ID: 26319883
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients.
    Peña-Lorenzo D; Rebollo N; Sánchez-Hernández JG; Zarzuelo-Castañeda A; Vázquez-López L; Otero MJ; Pérez-Blanco JS
    Eur J Pharm Sci; 2022 Jan; 168():106049. PubMed ID: 34699939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.